12 Nov 09 FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma

The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin) is injectable and is marketed by Gloucester Pharmaceuticals Inc of Cambridge, Massachusetts. Every year, about 1,500 Americans are newly diagnosed with CTCL, a type of non-Hodgkin’s lymphoma.

Related Posts:

FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma Gloucester Pharmaceuticals announced today that the U.S. Food and Drug...
FDA Advisory Committee Recommends Gloucester Pharmaceuticals’ Romidepsin For Approval For Cutaneous T-cell Lymphoma Gloucester Pharmaceuticals announced that the Oncologic Drug Advisory Committee (ODAC)...
FDA Approves Drug Treatment For Rare Cancer The U.S. Food and Drug Administration has approved Istodax (romidepsin),...
FDA Approves First Drug For Treatment Of Peripheral T-cell Lymphoma The U.S. Food and Drug Administration has approved Folotyn (pralatrexate),...
Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cutaneous T-cell Lymphoma Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced...
Allos Therapeutics’ FOLOTYN™ Shows Activity In A Dose Finding Phase 1 Study Of Relapsed Or Refractory Cutaneous T-Cell Lymphoma Allos Therapeutics, Inc. (NASDAQ: ALTH) announced updated data from its...